Novo Nordisk Inc. (NASDAQ: NVO) stock gained by 1.59% at last close while the NVO stock price rises by 0.16% in the pre-market trading session. Novo Nordisk is a renowned worldwide healthcare firm headquartered in Denmark and founded in 1923. NVO’s mission is to inspire change in the fight against diabetes and other significant chronic diseases including obesity, as well as uncommon blood and endocrine abnormalities.
The US Food and Drug Administration authorized Wegovy which is the leading brand for a once-weekly semaglutide 2.4 mg injectable in the US, for chronic weight control, according to Novo Nordisk. Adults with obesity (starting BMI 30 kg/m2) or overweight (starting BMI 27 kg/m2) with at least one weight-related illness should use Wegovy as an addition to diet and exercise for chronic weight control.
Wegovy is the first but only given once-a-week glucagon-like peptide-1 (GLP-1) receptor agonist medication licensed for obese weight control. The decision was made based on the findings of the STEP phase 3a clinical study. Persons with obesity treated with Wegovy saw an average weight loss of 17-18 percent 1 over 68 weeks in studies in people without type 2 diabetes. Throughout the program, Wegovy revealed a safe and well-tolerated profile, with the most prevalent adverse reactions being gastrointestinal.
Martin Holst Lange, executive vice president, Development at Novo Nordisk stated:
Wegovy’s approval in the United States holds a lot of potential for obese individuals. Many persons with obesity suffer to lose weight and keep it off despite their best efforts because of physiological processes that encourage weight growth. Wegovy’s remarkable weight loss for an anti-obesity medicine ushers in a new era in the treatment of obesity, and NVO is excited to make it available to patients living with obesity in the United States.
However, the anticipated date given by Novo Nordisk for the launch of Wegovy in the USA is in late June 2021.